- Guardant Health (GH, Financial) and Pfizer (PFE) enter a multi-year global collaboration using Guardant's liquid biopsy platform.
- The partnership focuses on evaluating circulating tumor DNA (ctDNA) for therapy response monitoring.
- Guardant's tests will be used in Pfizer's clinical studies, including those in China.
Guardant Health, Inc. (GH), a leader in precision oncology, has announced a strategic collaboration with Pfizer, Inc. (PFE) to enhance the development and commercialization of new cancer therapies through the use of Guardant's Infinity™ smart liquid biopsy platform. This multi-year agreement is poised to utilize Guardant’s advanced liquid biopsy tests in Pfizer’s worldwide clinical research, placing a significant emphasis on the clinical utility of circulating tumor DNA (ctDNA) for monitoring therapy responses.
The collaboration aims to leverage Guardant's liquid biopsy portfolio to support Pfizer’s oncology programs globally, including the evaluation of ctDNA as a potential surrogate endpoint in therapy response. Furthermore, the agreement grants Pfizer access to Guardant’s liquid biopsy tests in China, an area where cancer remains the leading cause of death, with over three million reported cancer-related deaths in 2020.
Guardant Health is committed to transforming cancer care through innovative blood and tissue tests, real-world data, and AI analytics. Established in 2012, the company continues to push advancements in guiding clinical decision-making in cancer treatment, from early-stage screening to advanced cancer management. This partnership with Pfizer represents a crucial step toward enhancing precision medicine and expanding access to innovative cancer diagnostics.
